Sign In
Buy CODX
$1.44
-0.120 (-7.69%)
At Close: Jul 31, 2026
Co-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in Development
09:30am, Thursday, 02'nd Nov 2023
Company to use funds awarded by the Bill & Melinda Gates Foundation toward the tuberculosis test for its Co-Dx™ PCR platform SALT LAKE CITY , Nov. 2, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasda
Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for November 2023
09:30am, Tuesday, 31'st Oct 2023
SALT LAKE CITY , Oct. 31, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o
Co-Diagnostics, Inc. Announces Third Quarter 2023 Earnings Release Date and Webcast
09:30am, Thursday, 26'th Oct 2023
SALT LAKE CITY , Oct. 26, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. to Host Booth at CASMET Symposium October 23-25
09:30am, Monday, 23'rd Oct 2023
SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o
Sustainable Infrastructure Dividend ETF Distributions
09:18am, Monday, 23'rd Oct 2023
TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Middlefield Sustainable Infrastructure Dividend ETF (TSX: MINF) (the “Fund”) is pleased to announce that distributions for the fourth quarter of 2023 wil
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
06:16pm, Thursday, 10'th Aug 2023
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.10 per share a year ago.
Co-Diagnostics, Inc. Announces Second Quarter 2023 Earnings Release Date and Webcast
09:30am, Thursday, 27'th Jul 2023
SALT LAKE CITY , July 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. (CODX) Q1 2023 Earnings Call Transcript
10:33pm, Thursday, 11'th May 2023
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian B
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates
07:02pm, Thursday, 11'th May 2023
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.26 per share a year ago.
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates
07:05pm, Thursday, 16'th Mar 2023
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto
Co-Diagnostics, Inc. (CODX) Q4 2022 Earnings Call Transcript
06:37pm, Thursday, 16'th Mar 2023
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman, President and Chi
CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST
09:30am, Thursday, 09'th Mar 2023
SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. to Present and Host Booth at TRI-CON in San Diego, CA, March 6-8
09:30am, Thursday, 02'nd Mar 2023
SALT LAKE CITY , March 2, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of m
Co-Diagnostics ends 3Q with $86.5M in cash; makes significant progress on its Co-Dx PCR Home platform
09:53am, Friday, 11'th Nov 2022
Co-Diagnostics Inc (NASDAQ:CODX) posted financial results for the third quarter that revealed ample cash on hand, giving the company scope to further advance its Co-Dx PCR Home testing platform for in
Co-Diagnostics, Inc. (CODX) Q3 2022 Earnings Call Transcript
10:41pm, Thursday, 10'th Nov 2022
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Dan Bohrer - VP, Finance and Accounting Dwight Egan - CEO Brian Brown - CFO Confe
